Bharat Biotech assures efficacy of India's Covid-19 vaccine candidate
New Delhi, Nov 22 (Prensa Latina) India's biotechnology Bharat Biotech company assured on Sunday that its vaccine candidate against Covid-19 called Covaxin will have an effectiveness of at least 60 percent.
Bharat Biotech Chairman of Quality Operations Sai D Prasad said that both the World Health Organization (WHO) and India's Central Drug Standards Control Organization approve a vaccine against respiratory diseases if the vaccine has at least 50 per percent of effectiveness, the News18 website revealed.
The company said that while it aimed to achieve at least 60 percent of effectiveness as a minimum criterion, it is now trying to reach a higher rate, adding that the launch of the vaccine is scheduled for mid-2021, when it receives the corresponding approvals.
Bharat Biotech manufactured the first Indian vaccine candidate against Covid-19 and began phase III clinical trials of the biotech product at the beginning of the month, with 26,000 volunteers in 25 centers in the country.
Such clinical trial, in collaboration with the Indian Council for Medical Research, is the largest ever conducted for a Covid-19 vaccine candidate in India.
The test volunteers, all adults over 18 years old, will receive two six-microgram intramuscular injections of Covaxin or a placebo, with an interval of 28 days.
The highly purified and inactivated indigenous Indian vaccine for Covid-19 is expected to be the cheapest in the world.
|By the minute||Most read|